MedTrace Logo

Radioimmunoimaging of AL Amyloidosis

NCT00807872 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2013-09-18

No results posted yet for this study

Summary

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

Conditions

  • Primary Amyloidosis

Interventions

BIOLOGICAL

124I-labeled monoclonal antibody Mu 11-1F4

Single infusion of radiolabeled antibody: 2 mCi (1 mg)

Sponsors & Collaborators

  • FDA Office of Orphan Products Development

    collaborator FED

  • University of Tennessee

    lead OTHER

Principal Investigators

  • Alan Solomon, MD · University of Tennessee Graduate School of Medicine

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2012-03-31
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00807872 on ClinicalTrials.gov